Raf/MEK/Erk signaling is activated in the majority of acute myeloid leukemias (AMLs), providing rationale for targeting this pathway with therapeutic intent. We investigated growthinhibitory and proapoptotic effects of sorafenib in AML. Our studies demonstrated that sorafenib significantly inhibited the phosphorylation levels of Raf downstream target proteins MEK1/2 and Erk, induced apoptosis and inhibited colony formation in AML cell lines and in primary AML samples. Mechanistically, treatment with sorafenib resulted in upregulation of proapoptotic Bim, accompanied by an increase in Bad, Bax and Bak protein levels and decreased Mcl-1, X-linked inhibitor of apoptosis and surviving levels, which mainly led to the activation of the intrinsic apoptotic pathway. Silencing of Bim protein expression significantly abrogated sorafenibinduced apoptosis, suggesting a critical function of Bim in the activation of the intrinsic mitochondrial pathway induced by sorafenib. Importantly, sorafenib also modulated phospho-Erk, Bim, Bax and Mcl-1 levels in samples procured from patients in an ongoing Phase I clinical trial of sorafenib in AML. Combination of sorafenib with cytarabine or the novel small molecule Bcl-2 inhibitor ABT-737 synergistically induced cell death in AML cell lines. Our results strongly suggest potential activity of sorafenib as a novel mechanism-based therapeutic agent in AML.
Introduction
The mitogen-activated protein kinase (MAPK) or Ras/Raf/MEK/ Erk signaling cascade constitutes an ubiquitous intracellular signaling pathway that transmits mitogenic stimuli to the nucleus through a series of sequential phosphorylation events and controls such cellular functions as proliferation, differentiation and apoptosis. 1, 2 Our previous studies demonstrated that MAPK signaling is constitutively activated in more than 50% of primary acute myeloid leukemia (AML) samples 3 and is an independent prognostic factor for survival. 4, 5 Raf, the bestcharacterized downstream effector kinase of Ras, is one of the protooncogenes in Ras/Raf/MEK/Erk kinase signaling. Raf is principally activated by phosphorylation, and then propagates signaling by phosphorylating the two dual-specificity MAPKKs, MEK1 and MEK2. The respective downstream substrates of MEK1 and MEK2 are Erk1 (p44
MAPK
) and Erk2 (p42 MAPK ). The activation of Raf/MEK/Erk kinase triggers re-entry into the cell cycle 6 and affects apoptosis by inhibiting the proapoptotic activity of BH3-only proteins Bim and Bad and that of the 'executioner' proapoptotic proteins Bax and Bak, 7, 8 and additionally by antagonizing the function of antiapoptotic Bcl-2 family proteins, including Bcl-X L and Mcl-1. 9, 10 In response to certain apoptotic stimuli, Bim can be released from microtubules and translocates to mitochondria, where it binds to Bcl-2 and Bcl-X L and promotes apoptosis either by neutralizing the antiapoptotic activity of Bcl-2 or Bcl-X L via formation of Bim/ Bcl-2 or Bim/Bcl-X L heterodimers, 11 or by directly activating the Bax-mediated cell death pathway. 12 However, the precise molecular mechanisms of action of Bcl-2 family proteins are still under investigation.
Sorafenib is a small molecule Raf kinase inhibitor 13 that has shown efficacy in preclinical and phase I/II clinical trials in patients with solid tumors. [14] [15] [16] [17] On the basis of recent reports, it is now acknowledged that sorafenib is in fact a multikinase inhibitor that in addition to Raf targets the vascular endothelial growth factor receptors (VEGFR-2 and VEGFR-3) and the platelet-derived growth factor receptor family (PDGFR-beta and Kit). 14, 18 Recently, sorafenib has shown dramatic effects in AML cells harboring FLT3-ITD mutations, both in vitro and in a phase I clinical trial. [19] [20] [21] However, further studies of sorafenib in AML without FLT3 mutations, which represent 70 percent of AML patients, are valuable for understanding its therapeutic potential in leukemias. In this study, we investigated efficacy and mechanisms of action of sorafenib in AML cell lines and primary AML samples, both in vitro and ex vivo in leukemic blasts from patients undergoing sorafenib treatment in an ongoing Phase I clinical trial. Our results demonstrate that sorafenib potently inhibited Raf/MEK/Erk signaling and induced growth arrest and apoptosis in AML cells. Upregulation of the BH3-only protein Bim plays a critical role in sorafenib-induced apoptosis, augmented by changes in other Bcl-2 family proteins Mcl-1 and Bax.
Materials and methods

Reagents and cell lines
Sorafenib was provided by Bayer Pharmaceuticals Co. (West Haven, CT, USA). The small molecule Bcl-2 family inhibitor, ABT-737 22 was synthesized at M. D. Anderson Cancer Center based on the published structure. Cytarabine (Ara-C) was from Skye Pharmaceutical Inc. (San Diego, CA, USA). The human AML cell lines U937, HL60, KG-1 and OCI/AML3 were used for these studies. Bone marrow and peripheral blood primary samples were obtained from patients with newly diagnosed or recurrent AML or from patients with advanced, relapsed or refractory AML or MDS (Table 1) . Informed consent was obtained following institutional guidelines.
Cell viability analysis and apoptosis assays
Cell viability was assessed using the trypan blue dye exclusion method, and apoptosis was measured by flow cytometry using Annexin V staining, as described previously. 23 
Immunoblotting and immunoprecipitation analyses
For the immunoblotting and immunoprecipitation studies, total cell lysates were pulled down by antibody/protein A/G PLUSagarose or directly analyzed by Western blot in standard procedures using corresponding antibodies as described previously. 24 
Lentiviral transduction of Bim shRNA
Bim expression was silenced by infecting U937 cells with short hairpin RNA (shRNA)-encoding oligonucleotide targeting BIM (Dharmacon Inc., Chicago, IL, USA). The cells were treated with sorafenib for 48 h. The proportion of transduced cells undergoing apoptosis was stained with allophycocyanin-conjugated Annexin V and measured by flow cytometry.
Immunofluorescence staining and confocal analyses U937 cells were treated with 2.5 mM sorafenib for 3 h and stained with indicated antibodies and Mitotracker (CMXRos). Colocalization was observed under a confocal laser-scanning microscope (Olympus FV500).
AML blast colony and soft agar assays
For the colony formation assay, primary bone marrow blast cells were used to determine AML blast colony formation by a previously described method. 25 For AML cell lines, OCI/AML3 and U937 cells were seeded in low-melting agarose in the presence of different concentrations of sorafenib or vehicle and incubated for 14 days. Colonies were then stained with p-iodonitrotetrazolium violet for 16 h. Colonies larger than 100 mm in diameter were counted under a microscope in triplicate wells.
Phase I patient sample analyses
Whole-blood samples acquired from patients of sorafenib Phase I clinical trial according to institutional guidelines (Table 1) were collected at baseline and at 2, 24 and 120 h after administration of sorafenib during the first course of therapy. Peripheral blood cells were isolated after removing red blood cells for evaluating apoptosis by Annexin V staining. For the phospho-Erk analyses, cells were fixed in 2% paraformaldehyde/phosphate-buffered saline, stained with allophycocyanin-conjugated CD34 and phycoerythrin-conjugated phospho-Erk antibodies, and phospho-Erk levels were determined by flow cytometry.
Analysis of combined effects of drugs
For the analysis of the combined effects of drugs, OCI/AML3 cells were simultaneously exposed to both sorafenib and Ara-C for 48 h or pretreated with sorafenib for 4 h and then treated with ABT-737 (a Bcl-2 inhibitor) for another 48 h. The inhibition of cell growth was determined by the trypan blue dye exclusion method. The combination index (CI) method was used to calculate combined drug effects by CalcuSyn (BioSoft, Ferguson, MO, USA) software. A CI of o1, 1 and 41 indicates synergism, an additive effect and antagonism, respectively. Combined drugs were used at fixed molar ratios. The drug doses that inhibited cell growth by about 50% in single-drug experiments were used to determine an appropriate fixed molar ratio of the two drugs combined.
Statistical analyses
Results are expressed as means ± s.e.m. Levels of significance were evaluated by a two-tailed paired Student's t test, and Po0.05 was considered significant.
The details of the Materials and methods, including antibodies and chemicals, cell lines and primary patient samples, immunoprecipitation analyses, lentiviral transduction, immunofluorescence staining and confocal analyses, AML blast colony and soft agar assays, and Phase I patient sample analyses, are available online as Supplementary Information.
Results
Sorafenib induces dephosphorylation of MEK1/2 and Erk proteins and apoptosis in AML cells
First, we investigated inhibitory effects of sorafenib on phosphorylation of Raf downstream target proteins MEK1/2 and Erk in human leukemic cells OCI/AML3, HL60, U937 and KG-1. Results showed a dose-dependent inhibition in all four AML cell lines, regardless of their baseline levels of Erk activation ( Figure 1a ). Of note, plasma concentrations of sorafenib in Phase I clinical trials have been reported to be in the 10.7-15 mM range, which exceeds the concentrations used here. 17 We next investigated the effects of sorafenib on inducing leukemia cell apoptosis. Our results demonstrate that the ability of sorafenib to induce AML cell apoptosis depends on baseline levels of Erk activation. OCI/AML3 and HL60 cells, in which Erk is constitutively activated, 26 were more sensitive to the inhibitory effects of sorafenib than U937 and KG-1 cells (Figure 1b) , in which activity of Erk is growth factor dependent (IC 50 s: 0.39 and 1.14 mM vs 2.86 and 2.80 mM, respectively, at 72 h of exposure to sorafenib) (data shown in Supplementary  Figure 1 ). In primary AML samples cultured in vitro, 5 mM sorafenib induced apoptosis in five of six samples tested after 72 h (range, 46-60% Annexin V( þ ) cells), while no significant apoptosis induction was observed in normal bone marrow cells of three normal donors ( Figure 1c ).
The damage of mitochondrial function is involved in sorafenib-modulated proapoptotic effect
We next investigated the molecular mechanisms of apoptosis induction by sorafenib in AML. Cleavage of caspase-9 and -3 was observed at lower concentrations of sorafenib (1 and 2.5 mM) in OCI/AML3 and U937 cells. In contrast, moderate cleavage of caspase-8 was observed after prolonged (48 h) sorafenib treatment and only at higher concentrations (5 mM) (Figure 2a ). Leukemic cells with mutated caspase-8 protein exhibited unchanged sensitivity to sorafenib (data shown in Supplementary Figure S2 ). Cell apoptosis was accompanied by the loss of mitochondrial membrane potential and cytochrome c release (Figures 2b and c) . Levels of inhibitor-of-apoptosis proteins survivin and X-linked inhibitor of apoptosis decreased after 48 h (5 mM of sorafenib) in OCI-AML3, but not in U937 cells (Figure 2a ).
Bim plays a crucial role in sorafenib-induced cell apoptosis
To examine the role of the Bcl-2 family proteins in sorafenibinduced apoptosis, we investigated effects of sorafenib on the expression levels of these proteins. Time course analysis showed that sorafenib at 2.5 mM increased BH3-only protein Bim levels as early as 3 h after drug exposure. Simultaneously, levels of proapoptotic proteins Bad, Bax and Bak consistently increased at that time point. In contrast, the antiapoptotic protein Mcl-1 was downregulated in both OCI/AML3 and U937 cells. No appreciable changes in Bcl-2 or Bcl-X L levels were observed ( Figure 3a) .
Considering that the BH3-only protein Bim is traditionally characterized as a direct 'activator' of Bax/Bak, 27, 28 we silenced Bim expression by introducing Bim shRNA into U937 cells to determine its functional role in sorafenib-induced apoptosis. Bim knockdown dramatically protected U937 cells from sorafenib-induced apoptosis (scrambled: 73%±0.53 vs Bim-shRNA: 28% ± 1.69 Annexin V ( þ ) cells) (Figure 3b ). translocation of Bim from microtubules to mitochondria. This was confirmed by immunoprecipitation/Western blot studies, which showed progressive decrease of the level of tubulinbound Bim, while the levels of Bim co-immunoprecipitated with Bcl-X L increased in response to increasing concentrations of sorafenib (Figure 3d ).
Sorafenib abrogates colony formation of primary AML and OCI/AML3 cells
Next, we examined effects of sorafenib on the clonogenic ability of AML cell lines and primary AML samples. Sorafenib inhibited colony formation of OCI/AML3 and U937 cells by 50% at 0.64±0.14 and 6.85±0.64 mM, respectively (Figure 4a) , and of primary AML samples at 2.68 ± 1.76 mM (Figure 4b ). In contrast, no inhibition of normal bone marrow colony formation was observed up to 2.5 mM (data shown in Supplementary Figure 3) . These results suggest that AML progenitors are significantly more sensitive to inhibitory effects of sorafenib than normal bone marrow cells. externalization of phosphatidylserine detected with Annexin V in AML blasts was evident in samples from all patients (Figure 5a ). Phospho-Erk levels were downregulated in CD34 þ blasts after 24 or 120 h of sorafenib administration as measured by flow cytometry (Figure 5b ). Immunoblot analysis showed upregulation of Bim and Bax and concomitant Mcl-1 downregulation in these samples (Figure 5c ), in concordance with our results in cell lines in vitro. Impressively, peripheral blasts decreased from 10 and 55 to 1 and 46% in case no. 1 and 3, respectively, after 14 days of sorafenib administration (data not shown).
Combined inhibition of Raf and chemotherapy, or Raf and Bcl-2 signaling synergistically inhibits growth of AML cells
Because cytotoxic agents may be less effective when antiapoptotic mechanisms are enhanced by constitutively activated Raf/ MEK/Erk signaling, we tested the combined effects of sorafenib and Ara-C, the most efficacious cytotoxic agent used in AML therapy. Indeed, a significant synergistic effect was seen in OCI/ AML3 cells simultaneously exposed to sorafenib and Ara-C at a fixed molar ratio (2:1) for 48 h, with an averaged CI at ED 50 , ED 75 and ED 90 of 0.279±0.077 (Figure 6a ). Taking into consideration that sorafenib does not affect levels of antiapoptotic Bcl-2, we next examined combined effects of sorafenib and the small molecule Bcl-2 inhibitor ABT-737. 22 Pretreatment of OCI-AML3 cells with sorafenib for 4 h followed by exposure to ABT-737 for another 48 h showed pronounced synergism, with an average CI of 0.318±0.050 (Figure 6b ). These results suggest that sorafenib has potential in combination with chemotherapy or Bcl-2 inhibitors in AML patients with constitutively phosphorylated Erk.
Discussion
In the present study, we demonstrated that sorafenib suppressed the phosphorylation of downstream target proteins of Raf, MEK and Erk, in human AML cell lines regardless of whether Erk was constitutively activated. However, we observed a significant correlation between growth-inhibitory and proapoptotic effects of sorafenib and basal levels of phosphorylated MEK and Erk in AML cell lines, suggesting that the constitutive activation of this pathway renders leukemia cell survival dependent on this pathway. Conversely, the lack of constitutive MAPK activation in normal hematopoietic progenitors may explain their relative resistance to Raf inhibition, as observed in clonogenic assays with normal bone marrow samples in this study (data shown in Supplementary Figure 3) and in our previous studies using MEK Our present data demonstrated that inhibition of the Raf/MEK/ Erk pathway by sorafenib induced apoptosis not only in primary AML samples and AML cell lines but also, most importantly, in samples obtained from AML patients participating in a Phase I trial of sorafenib (Figure 5a ). Mechanistically, in our in vitro studies, induction of apoptosis occurred mainly via the intrinsic apoptotic pathway, as manifested by the loss of the mitochondrial membrane potential, early cytochrome c release, activation of caspase-9 and its downstream effector caspase-3, and the downregulation of survivin and X-linked inhibitor of apoptosis that we reported earlier for another MEK inhibitor. 29 On the contrary, caspase-8 cleavage was seen only in response to prolonged treatment with high concentrations of sorafenib. We further compared the efficacy of sorafenib in both caspase-8 mutant Jurket and control cells and found a similar degree of apoptosis induction (data shown in Supplementary Figure 2) , suggesting that caspase-8 is likely not a critical player in sorafenib-induced AML apoptosis.
Considering the pivotal role of Bcl-2 family proteins in the regulation of the intrinsic pathway, we investigated effects of sorafenib on Bcl-2 family proteins. Sorafenib upregulated proapoptotic proteins Bim, Bad, Bax and Bak and reduced the antiapoptotic protein Mcl-1. Bax and Bak are 'executioner' proapoptotic proteins, which require activation via BH3-only proteins. 28 Of all BH3-only proteins examined, only Bim and tBid are known to have the capacity to act as direct activators of Bax and Bak. We focused our studies on Bim, which has recently emerged as one of the critical Bcl-2 family proteins in the hematopoietic system. [30] [31] [32] Bim is sequestered to the dynein motor complex and translocates to the mitochondria upon apoptotic stimuli. 11 Our data demonstrated early translocation (within a few hours) of Bim to the mitochondria, associated with decreased Mcl-1 and increased Bax within 3-6 h, followed by cytochrome c release after 6 h. Mitochondrially localized Bim may be bound and neutralized by antiapoptotic Bcl-2, Bcl-X L and Mcl-1. We propose that simultaneous induction of mitochondrially translocated Bim and downregulation of Mcl-1 will result in release of increased amounts of free Bim, which subsequently activates Bax or Bak. In addition, sorafenib is also capable of inducing expression of Bad, another BH3-only protein that functions as a 'sensitizer' and may bind and neutralize Bcl-2 and Bcl-X L proteins at the mitochondria. Lastly, mitochondrially localized Bak binds Bcl-X L and Mcl-1, and our recent studies showed that Bak is tightly associated with Mcl-1 in OCI/AML3 cells. 33 Hence, it is plausible that increased levels of Bak and Bad directly bind and neutralize remnant levels of Mcl-1 (Bak) and Bcl-2/Bcl-X L (Bad), thus promoting Bax activation by freed Bim. Silencing Bim by shRNA dramatically protected U937 cells from sorafenib-induced apoptosis and strongly implies Bim as a critical factor in sorafenib-modulated leukemic cell apoptosis. Importantly, modulation of phosphoErk, Bim, Mcl-1 and Bax was also observed in samples from AML patients undergoing sorafenib therapy in vivo in the ongoing Phase I clinical trial (Figures 5b and c) .
The constitutive activation of the MEK/Erk signaling module increases the apoptotic threshold of cancer cells, consistent with its ability to regulate the expression and function of multiple antiapoptotic regulators via transcriptional and non-transcriptional mechanisms. 7, 34 One of the most intriguing features of Raf/MEK/Erk inhibitors is their ability to lower the apoptotic threshold of leukemic cells, thereby sensitizing them to the proapoptotic effects of other biological agents and chemotherapeutics. 35 Since Ara-C has been shown to activate the cytoprotective Erk pathway, 36 inhibition of this pathway by sorafenib in combination with Ara-C may lower the apoptotic threshold. On the other hand, lowering Mcl-1 levels has been shown to play a critical role in sensitizing effects of MAPK inhibitors to apoptosis induction by small molecule Bcl-2 inhibitor ABT-737 in AML cells otherwise resistant to this agent. 33 Sorafenib-induced downregulation of Mcl-1 and upregulation of Bim level may also sensitize to a variety of proapoptotic stimuli. We reasoned that combining Ara-C or ABT-737 with sorafenib might be a valuable strategy to enhance sorafenib-induced apoptosis. Our findings indeed demonstrated significant synergistic effects by combining sorafenib with either Ara-C or ABT-737 (Figures 6a and b) . The direct benefit of such combination therapies may allow to lower drug dose administered and thereby to diminish toxicity and enhance leukemic cell killing in vivo. This approach may be especially beneficial for the therapy of resistant AML, which expresses high Bcl-2 levels. 37 These broad implications of our findings will await the conduct of further in vivo or clinical studies to realize their full potential. Figure 6 Combination treatment with sorafenib and Ara-C or ABT737 synergistically inhibits OCI/AML3 leukemic cell proliferation. (a) OCI/AML3 cells were treated with sorafenib and Ara-C simultaneously for 48 h or (b) pretreated with sorafenib for 4 h and then added ABT-737 for 48 h at fixed molar ratios (2:1). The growth-inhibitory effects were evaluated by trypan blue dye exclusion. CI plots were generated using the Calcusyn software (symbols represent actual data points for the combination). CI values of less than 1.0 indicate synergism. The average CIs at ED 50 , ED 75 and ED 90 were 0.279 ± 0.077 and 0.318 ± 0.050, respectively. AML, acute myeloid leukemia; Ara-C, cytarabine; CI, combination index.
In summary, sorafenib induces apoptosis in both AML cell lines and primary AML samples, and importantly, in cells from AML patients undergoing a phase I clinical trial of sorafenib. Our data strongly indicate the ability of sorafenib to induce apoptosis in a Bim-dependent manner, likely as a consequence of the disturbed balance between Bim, Bax, Bad and Mcl-1. Furthermore, synergistic effects of combining sorafenib with Ara-C or ABT-737 lower the threshold of sorafenib-induced cell death and demonstrate the potential of sorafenib alone or in combination as a novel mechanism-based therapeutic agent in AML therapy.
